Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan. And we're continuing the 2021 health care conference today with Mersana. Just a quick housekeeping note. (Operator Instructions)
So with that out of the way, let me turn it over to Mersana's CEO, Anna Protopapas.
Thank you, Jess. And I should mention that in the Q&A session, I'll be joined by Tim Lowinger, our Chief Science and Technology Officer; Arvin Yang, our CMO; and Brian DeSchuytner, our Head of Finance, Strategy and Business Development. But let me start on Slide 2. Before I go through the presentation, I do want to remind you that I will be making forward-looking statements.
Moving on to Slide 3. In the past few years, the introduction of new ADC therapies has accelerated. We now have 9 ADCs on the market and almost 100 in clinical development. Mersana was founded on the vision that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
